Skip to main content

Treatment of Nonunions with Nonglycosylated Recombinant Human Bone Morphogenetic Protein-2 Delivered from aFibrinMatrix

Buy Article:

$51.00 plus tax (Refund Policy)



To report the results of the treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 (nglBMP-2) delivered from a designed fibrin matrix. Study Design

Experimental trial in rodents and prospective clinical study in dogs and cats with nonunion fractures. Animals

Twenty adult female, albino, Sprague–Dawley rats; 8 client-owned cats and dogs. Methods

After development of a fibrin matrix and evaluation of nglBMP-2 in a rodent femoral defect model, 8 consecutive long bone nonunion fractures (no progression in healing in ≥3 months), were treated using 300 g nglBMP-2 in a liquid fibrin precursor, injected into the defect gap after fracture revision and stabilization, or through a stab incision into the fracture site. The fibrin matrix was designed to clot in the wound after 60 seconds and to release the nglBMP-2 continuously over several days. Results

Using only fibrin gel, 7% of the rat femoral defect was filled with new formed bone compared with 79% defect filling using 2g nglBMP-2 (P=.006). Five and 10 g nglBMP in fibrin resulted in union of all femoral defects with complete filling of the gap with new bone. Bony bridging and clinical healing was achieved in 7 patients within 24 weeks of administration of nglBMP-2. Conclusions

Application of nglBMP-2 in a functional matrix can induce bone healing. Controlled release of nglBMP-2 from a fibrin matrix mimics the natural fracture hematoma. Clinical Relevance

nglBMP-2/fibrin can successfully replace a cancellous bone autograft in fracture treatment with an associated reduction in graft donor site morbidity and surgical time.

Document Type: Research Article


Affiliations: From the Department of Clinical Veterinary Medicine, University of Berne, Berne; the Clinic for Maxillofacial Surgery, University Hospital, Zurich; the Institute for Biomedical Engineering ETH, Zurich; the Department of Veterinary Surgery, Musculoskeletal Research Unit, University of Zurich; and Kuros Biosurgery, Zurich, Switzerland.

Publication date: March 1, 2004


Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more